Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.

Authors

Jiahao Chen, Xiao-Yu Wu, Xiang Li, Qing Shi, Di Fu, Yun-Ruei Kao, Yan Zhu, Bo-En Wang, Hao-Xing Bian, Yan Zhao, Yun Tan, Li Wang, Peng-Peng Xu, Wei-Li Zhao

Published in

Blood cancer discovery. Jun 24, 2026. Epub Jun 24, 2026.

Abstract

Tumor-infiltrating clonal hematopoiesis (TI-CH) contributes to progression of non-hematologic cancers. CH is prevalent in peripheral blood of patients with diffuse large B-cell lymphoma (DLBCL), but TI-CH prevalence and clinical relevance remain largely unexplored. Here, through genome- and exome-wide sequencing of DLBCL biopsies and blood samples from 304 treatment-naïve patients, we identified TI-CH in 13.5% of cases, which emerged as an independent risk indicator for disease progression and death. TI-CH cases had enrichment of inflammatory myeloid signature revealed by gene expression profiling of tumor biopsies. In addition, we developed a TI-CH-associated prognostic signature (CAPS) based on 24 differentially expressed genes. High CAPS score correlated with poor survival across four patient cohorts, and remained significant in three cohorts after adjustment for patient age, sex, International Prognostic Index score, and cell-of-origin classification. Collectively, these findings establish a link between TI-CH and clinical outcomes and implicate inflammatory signature as the potential underlying basis.

PMID:
42341256
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.